Grufity logoGrufity logo
Stock Ideas
Stocks
Funds
Screener
Sectors
Watchlists
PHAT

PHAT - Phathom Pharmaceuticals Inc Stock Price, Fair Value and News

$16.07-0.53 (-3.19%)
Delayed as of 23 Oct 2024, 03:02 pm ET
Max Portfolio Pct.
Check
Valuation
Check

Stock Quality:

GPSDBMFI
Max Portfolio Pct.
Check
Valuation
Check
GPSDBMFI

PHAT Price Action

Last 7 days

6%

Last 30 days

-9.9%

Last 90 days

44.9%

Trailing 12 Months

77.2%

PHAT RSI Chart

AprJulOct020406080100

PHAT Valuation

Market Cap

989.3M

Price/Earnings (Trailing)

-3.33

Price/Sales (Trailing)

1.0K

Price/Free Cashflow

-4.56

PHAT Price/Sales (Trailing)

2024FebMarAprMayJunJulAug6007008009001K

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

PHAT Fundamentals

PHAT Revenue

Revenue (TTM)

682.0K

Rev. Growth (Qtr)

283.05%

JulOct2024Apr682K

PHAT Earnings

Earnings (TTM)

-297.1M

Earnings Growth (Yr)

-123.23%

Earnings Growth (Qtr)

-10.37%

201920202021202220232024-300M-250M-200M-150M-100M-50M0

PHAT Profitability

Operating Margin

75.51%

Return on Equity

127.06%

Return on Assets

-93.03%

Free Cashflow Yield

-21.93%

PHAT Investor Care

Shares Dilution (1Y)

4.91%

Diluted EPS (TTM)

-5.18

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Dec682K
Net sales
YearQ1Q2Q3Q4
20240000
2023000682.0K
Get all data in R, Python etc through our Historical Stock Data APIs

About Phathom Pharmaceuticals Inc

PHAT
Phathom Pharmaceuticals, Inc., biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. Phathom Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Florham Park, New Jersey.
 CEO
 WEBSITEphathompharma.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES112

Phathom Pharmaceuticals Inc Frequently Asked Questions

What is the ticker symbol for Phathom Pharmaceuticals Inc? What does PHAT stand for in stocks?

PHAT is the stock ticker symbol of Phathom Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Phathom Pharmaceuticals Inc (PHAT)?

As of Tue Oct 22 2024, market cap of Phathom Pharmaceuticals Inc is 989.26 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of PHAT stock?

You can check PHAT's fair value in chart for subscribers.

Is Phathom Pharmaceuticals Inc a good stock to buy?

The fair value guage provides a quick view whether PHAT is over valued or under valued. Whether Phathom Pharmaceuticals Inc is cheap or expensive depends on the assumptions which impact Phathom Pharmaceuticals Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for PHAT.

What is Phathom Pharmaceuticals Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue Oct 22 2024, PHAT's PE ratio (Price to Earnings) is -3.33 and Price to Sales (PS) ratio is 1.03 Thousand. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. PHAT PE ratio will change depending on the future growth rate expectations of investors.